Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Colorectal Cancer | Review

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Authors: Qin Yang, Jie Wang, Pingyong Zhong, Tinggang Mou, Hao Hua, Pan Liu, Fei Xie

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long non-coding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of lncRNA FAM83H-AS1 in tumors is not completely known.

Methods

In this meta-analysis, literature was collected up until February 5, 2020 through multifarious retrieval strategies by searching through electronic databases of PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang. A total of 14 studies that met the inclusion criteria with relevant clinical data and prognostic information were included in the meta-analysis.

Results

The combined results revealed that high expression of FAM83H-AS1 was associated with poor overall survival (OS) (HR = 1.63, 95% CI 1.24–2.14, P = 0.0004) in a variety of cancers. Additionally, upregulated FAM83H-AS1 expression was significantly correlated with tumor TNM stage (III/IV vs. I/II, OR = 2.40, 95% CI 1.36–4.23, P = 0.003) and lymph node metastasis (positive vs. negative, OR = 1.70, 95% CI 1.14–2.52, P = 0.008) in patients with cancer.

Conclusions

Our results of this meta-analysis indicated that elevated FAM83H-AS1 expression could predict poor prognosis in patients with cancer and suggested that FAM83H-AS1 might serve as a novel biomarker for cancer.
Literature
1.
Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription. 2014;5:e944014.CrossRef
2.
Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017;18:206.CrossRef
3.
Chen L, Dzakah EE, Shan G. Targetable long non-coding RNAs in cancer treatments. Cancer Lett. 2018;418:119–24.CrossRef
4.
Vitiello M, Tuccoli A, Poliseno L. Long non-coding RNAs in cancer: implications for personalized therapy. Cell Oncol. 2015;38:17–28.CrossRef
5.
Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24:257–77.CrossRef
6.
Ma YK, Shen TH, Yang XY. Upregulation of LncRNA FAM83H-AS1 in hepatocellular carcinoma promotes cell proliferation, migration and invasion by Wnt/beta-catenin pathway. Eur Rev Med Pharmacol Sci. 2019;23:7855–62.PubMed
7.
Da J, Liu P, Wang R, Bu L. Upregulation of the long non-coding RNA FAM83H-AS1 in gastric cancer and its clinical significance. Pathol Res Pract. 2019;215:152616.CrossRef
8.
Gong YB, Zou YF. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer. Eur Rev Med Pharmacol Sci. 2019;23:4656–62.PubMed
9.
Bi YY, Shen G, Quan Y, Jiang W, Xu F. Long noncoding RNA FAM83H-AS1 exerts an oncogenic role in glioma through epigenetically silencing CDKN1A (p21). J Cell Physiol. 2018;233:8896–907.CrossRef
10.
Shan H, Yang Y, Zhu X, Han X, Zhang P, Zhang X. FAM83H-AS1 is associated with clinical progression and modulates cell proliferation, migration, and invasion in bladder cancer. J Cell Biochem. 2019;120:4687–93.CrossRef
11.
Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.CrossRef
12.
Zhong Y, Wu X, Li Q, Ge X, Wang F, Wu P, et al. Long noncoding RNAs as potential biomarkers and therapeutic targets in gallbladder cancer: a systematic review and meta-analysis. Cancer Cell Int. 2019;19:169.CrossRef
13.
Arnes L, Liu Z, Wang J, Maurer C, Sagalovskiy I, Sanchez-Martin M, et al. Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Gut. 2019;68:499–511.CrossRef
14.
Baratieh Z, Khalaj Z, Honardoost MA, Emadi-Baygi M, Khanahmad H, Salehi M, et al. Aberrant expression of PlncRNA-1 and TUG1: potential biomarkers for gastric cancer diagnosis and clinically monitoring cancer progression. Biomark Med. 2017;11:1077–90.CrossRef
15.
Wang B, Guan G, Zhao D. Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt/beta-catenin signaling pathway. Biomed Pharmacother. 2020;125:109961.CrossRef
16.
Dou Q, Xu Y, Zhu Y, Hu Y, Yan Y, Yan H. LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein. Eur J Pharmacol. 2019;852:134–41.CrossRef
17.
Yang L, Xu L, Wang Q, Wang M, An G. Dysregulation of long non-coding RNA profiles in human colorectal cancer and its association with overall survival. Oncol Lett. 2016;12:4068–74.CrossRef
18.
Lu S, Dong W, Zhao P, Liu Z. lncRNA FAM83H-AS1 is associated with the prognosis of colorectal carcinoma and promotes cell proliferation by targeting the Notch signaling pathway. Oncol Lett. 2018;15:1861–8.PubMed
19.
Yang F, Lv SX, Lv L, Liu YH, Dong SY, Yao ZH, et al. Identification of lncRNA FAM83H-AS1 as a novel prognostic marker in luminal subtype breast cancer. Onco Targets Ther. 2016;9:7039–45.CrossRef
20.
Zhang J, Feng S, Su W, Bai S, Xiao L, Wang L, et al. Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep. 2017;7:42819.CrossRef
21.
Ma Y, Xu XL, Huang HG, Li YF, Li ZG. LncRNA TDRG1 promotes the aggressiveness of gastric carcinoma through regulating miR-873-5p/HDGF axis. Biomed Pharmacother. 2019;121:109425.CrossRef
22.
Yi T, Wang T, Shi Y, Peng X, Tang S, Zhong L, et al. Long noncoding RNA 91H over-expression contributes to the growth and metastasis of HCC by epigenetically positively regulating IGF2 expression. Liver Int. 2020;40:456–67.CrossRef
23.
Wu W, Zhao Y, Gao E, et al. LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p. J Cell Mol Med. 2020;24:441–50.CrossRef
24.
Jiang L, Zhao XH, Mao YL, Wang JF, Zheng HJ, You QS. Long non-coding RNA RP11-468E25 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6. J Exp Clin Cancer Res. 2019;38:465.CrossRef
25.
Fu D, Lu C, Qu X, Li P, Chen K, Shan L, et al. LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis. Aging. 2019;11:8374–85.CrossRef
26.
Shi D, Wu F, Mu S, Hu B, Zhong B, Gao F, et al. LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway. J Exp Clin Cancer Res. 2019;38:375.CrossRef
27.
Zhang N, Li Z, Bai F, Zhang S. PAX5-induced upregulation of IDH1-AS1 promotes tumor growth in prostate cancer by regulating ATG5-mediated autophagy. Cell Death Dis. 2019;10:734.CrossRef
28.
Wu H, Cao F, Zhou W, Wang G, Liu G, Xia T, et al. Long non-coding RNA FAM83H-AS1 modulates the SpA-inhibited osteogenicdifferentiation in human bone mesenchymal stem cells. Mol Cell Biol. 2020;40:e00362-19.CrossRef
29.
Wei R, Chen Y, Zhao Z, Gu Q, Wu J. LncRNA FAM83H-AS1 induces nucleus pulposus cell growth via targeting the Notch signaling pathway. J Cell Physiol. 2019;234:22163–71.CrossRef
30.
Shu C, Yan D, Mo Y, Gu J, Shah N, He J. Long noncoding RNA lncARSR promotes epithelial ovarian cancer cell proliferation and invasion by association with HuR and miR-200 family. Am J Cancer Res. 2018;8:981–92.PubMedPubMedCentral
31.
He X, Zheng Y, Zhang Y, Gan Y, Zhou Y, Liang H, et al. Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of gamma-synuclein in hepatocellular carcinoma cells. Oncotarget. 2017;8:9451–65.PubMed
32.
Yang L, Cui J, Wang Y, Tan J. FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer. Biomed Pharmacother. 2019;118:109342.CrossRef
33.
Deva MRA, Patel K, Korivi JS, Meenakumari B, Sundersingh S, Sridevi V, et al. Identification of lncRNAs associated with early-stage breast cancer and their prognostic implications. Mol Oncol. 2019;13:1342–55.
Metadata
Title
The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
Authors
Qin Yang
Jie Wang
Pingyong Zhong
Tinggang Mou
Hao Hua
Pan Liu
Fei Xie
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-1148-8

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Integrated analysis of immune-related genes in endometrial carcinoma

Primary research

Long noncoding RNA NEAT1 regulates radio-sensitivity via microRNA-27b-3p in gastric cancer

Primary research

Serum-derived three-circRNA signature as a diagnostic biomarker for hepatocellular carcinoma

Primary research

The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2

Correction

Correction to: RETRACTED ARTICLE: miR-484 suppresses proliferation and epithelial–mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells

Primary research

LncRNA MSC-AS1 aggravates nasopharyngeal carcinoma progression by targeting miR-524-5p/nuclear receptor subfamily 4 group A member 2 (NR4A2)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits